| Title: |
Usefulness of ultra-sensitive troponin to predict anthracyclines and trastuzumab related cardiac dysfunction |
| Authors: |
Del Castillo, S; Llamedo, C; Capdeville, S; Fileni, L; Scarponi, C; Belziti, C; Rossi, E; Falconi, M; Perez De Arenaza, D; Pizarro, R |
| Source: |
European Heart Journal ; volume 43, issue Supplement_2 ; ISSN 0195-668X 1522-9645 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2022 |
| Description: |
Background Cancer therapeutics–related cardiac dysfunction usually known as cardiotoxicity (CTX) is a common adverse effect of anthracyclines and anti-Her2 agents. In recent years, evidence of usefulness of ultrasensitive troponin for early diagnosis of CTX has increased, however the cut-off values of this biomarker remain uncertain. Purpose To assess the usefulness of ultrasensitive troponin T (UsTnT) to identify patients at risk of developing CTX and determine cut-off values for this biomarker. Methods Patients with diagnosis of solid or hematologic malignancies scheduled to receive therapy including anthracyclines and/or trastuzumab were prospectively included. Echocardiogram was performed prior to chemotherapy, and repeated 3 and 6 months later. UsTnT was measured at baseline and 3 months after starting chemotherapy and the increase of this biomarker from baseline was calculated. This UsTnT has a range of 3–10,000 pg/mL with a 99th percentile |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/eurheartj/ehac544.800 |
| Availability: |
https://doi.org/10.1093/eurheartj/ehac544.800; https://academic.oup.com/eurheartj/article-pdf/43/Supplement_2/ehac544.800/46363091/ehac544.800.pdf |
| Rights: |
https://academic.oup.com/pages/standard-publication-reuse-rights |
| Accession Number: |
edsbas.9C35AAC2 |
| Database: |
BASE |